Omvoh Approved for Crohn’s; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn’s disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 antagonist was previously approved for ulcerative colitis.

In Crohn’s disease patients, adherence to a Mediterranean diet was associated with better clinical outcomes and decreases in markers of inflammation, a prospective cohort study found. (Gastroenterology)

Physiological data captured passively from wearable devices like Fitbits or Apple Watches can predict inflammatory bowel disease (IBD) flares. (Gastroenterology)

Combing 5-aminosalicylic acid with ustekinumab (Stelara) did not appear to provide a clinical benefit in IBD, claims data suggested. (Inflammatory Bowel Diseases)

Meanwhile, adalimumab (Humira) could be a safe option for very early-onset IBD, retrospective data suggested. (Inflammatory Bowel Diseases)

Authors of a narrative review in Clinical Gastroenterology and Hepatology examined various lifestyle approaches and pharmacologics for reducing the risk of metabolic dysfunction associated steatotic liver disease (MASLD)-related liver cancer.

The investigational pan-peroxisome proliferator-activated receptor (PPAR) agonist lanifibranor showed promise in a phase II study of MASLD patients with diabetes. (Journal of Hepatology)

Frequency of polyp diagnoses among family members was linked with colorectal cancer (CRC) risk, especially early-onset cancers. (Gastroenterology)

Which noninvasive CRC screening options — i.e., fecal immunochemical testing, stool DNA tests, or blood-based assays — are most cost-effective in community clinics? (JAMA Network Open)

A clinical practice update from the American Gastroenterological Association weighed in on vaccinations and non-CRC cancer screenings for patients with IBD. (Clinical Gastroenterology and Hepatology)

In a placebo-controlled phase II trial, fecal microbiota transplant for preventing hepatic encephalopathy in patients with cirrhosis appeared safe and was associated with lower recurrence rates. (Journal of Hepatology)

Eradication of Helicobacter pylori reduced the risk of gastric cancer and death from gastric cancer, a meta-analysis of 11 randomized trials and 13 observational studies found. (Gastroenterology)

Please enable JavaScript to view the comments powered by Disqus.